Kharbanda S, Saleem A, Emoto Y, Stone R, Rapp U, Kufe D
Laboratory of Clinical Pharmacology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115.
J Biol Chem. 1994 Jan 14;269(2):872-8.
Treatment of human myeloid leukemia cells with 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C (PKC), is associated with induction of monocytic differentiation. Since PKC can act immediately upstream to the cytoplasmic Raf-1 serine/threonine protein kinase, we studied activation of Raf-1 during induction of the differentiated monocytic phenotype. The results demonstrate that Raf-1 is activated during TPA-induced monocytic differentiation of HL-60 cells. In contrast, there was little effect of TPA on this kinase in an HL-60 variant, designated HL-525, which is resistant to TPA-induced differentiation. Treatment of both HL-60 and HL-525 cells with okadaic acid, an inhibitor of serine/threonine protein phosphatases 1 and 2A, was associated with Raf-1 activation and induction of the monocytic phenotype. Since Raf-1 can activate the mitogen-activated protein (MAP) kinases, we also studied the relationship between MAP kinase activation and monocytic differentiation. Treatment of HL-60, but not HL-525, cells with TPA was associated with increased MAP kinase activity as determined by phosphorylation of myelin basic protein and the c-Jun Y peptide. Okadaic acid-induced differentiation of both HL-60 and HL-525 cells was similarly accompanied by increases in MAP kinase activity. These findings indicated that activation of Raf-1/MAP kinase signaling is associated with induction of a differentiated monocytic phenotype and that okadaic acid bypasses a defect in this cascade in TPA-treated HL-525 cells. While recent studies have shown that HL-525 cells are deficient in PKC beta, the present results demonstrate that PKC beta expression is up-regulated in the HL-525 variant by treatment with retinoic acid. The results also demonstrate that retinoic acid-treated HL-525 cells respond to TPA with activation of Raf-1 and MAP kinase, as well as induction of monocytic differentiation. Taken together, the results indicate that activation of Raf-1/MAP kinase signaling is associated with monocytic differentiation and that stimulation of serine/threonine protein phosphorylation by TPA or okadaic acid is sufficient for reversal of the leukemic HL-60 phenotype.
用蛋白激酶C(PKC)激活剂12 - O -十四烷酰佛波醇-13 -乙酸酯(TPA)处理人髓性白血病细胞,与单核细胞分化的诱导相关。由于PKC可在细胞质Raf - 1丝氨酸/苏氨酸蛋白激酶的紧邻上游发挥作用,我们研究了在分化单核细胞表型诱导过程中Raf - 1的激活情况。结果表明,在TPA诱导HL - 60细胞单核细胞分化过程中Raf - 1被激活。相比之下,TPA对一种名为HL - 525的HL - 60变体中的这种激酶几乎没有影响,该变体对TPA诱导的分化具有抗性。用丝氨酸/苏氨酸蛋白磷酸酶1和2A的抑制剂冈田酸处理HL - 60和HL - 525细胞,均与Raf - 1激活和单核细胞表型的诱导相关。由于Raf - 1可激活丝裂原活化蛋白(MAP)激酶,我们还研究了MAP激酶激活与单核细胞分化之间的关系。用TPA处理HL - 60细胞(而非HL - 525细胞),髓鞘碱性蛋白和c - Jun Y肽磷酸化检测结果显示,MAP激酶活性增加。冈田酸诱导HL - 60和HL - 525细胞分化同样伴随着MAP激酶活性增加。这些发现表明,Raf - 1/MAP激酶信号通路的激活与分化单核细胞表型的诱导相关,并且冈田酸绕过了TPA处理的HL - 525细胞中该信号级联的缺陷。虽然最近的研究表明HL - 525细胞中PKCβ缺乏,但目前的结果表明,用维甲酸处理可使HL - 525变体中PKCβ表达上调。结果还表明,用维甲酸处理的HL - 525细胞对TPA的反应是Raf - 1和MAP激酶激活以及单核细胞分化诱导。综上所述,结果表明Raf - 1/MAP激酶信号通路的激活与单核细胞分化相关,并且TPA或冈田酸刺激丝氨酸/苏氨酸蛋白磷酸化足以逆转白血病HL - 60表型。